Roughly 11.5% of carriers hit the recommended HbA1c target of below 7%, versus about a quarter of non-carriers
Given the rapid evolution of this field, future breakthroughs, including new drug approvals and expanded indications, necessitate systematic updates of the literature
Limitations, Side Effects and Unanswered Questions Some concerns around GLP-1s, notably insurance approval and out-of-pocket cost, will remain a consideration regardless of intended use
Why Meal Prep Is Non-Negotiable on GLP-1 Medications GLP-1 receptor agonists like semaglutide and tirzepatide work by slowing gastric emptying and signaling your brain that youre full
They help define the magnitude of GcgR agonism that can be tolerated in the context of GLP-1R agonism, as well as the degree of additional efficacy that it might yet be possible to achieve